Close Menu

NEW YORK – OncoCyte's shares fell nearly 29 percent to $2.85 in Wednesday morning trading on the Nasdaq after the company announced that it will need additional time to complete its ongoing CLIA validation study of its DetermaVu liquid biopsy test for lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.